Sign In
Buy ABUS
$4.35
+0.0900 (+2.11%)
At Close: Jun 03, 2026
Arbutus Biopharma Corporation (ABUS) CEO Bill Collier on Q4 2020 Results - Earnings Call Transcript
12:39pm, Thursday, 04'th Mar 2021
Arbutus Biopharma Corporation (ABUS) CEO Bill Collier on Q4 2020 Results - Earnings Call Transcript
Arbutus Biopharma (ABUS) Reports Q4 Loss, Tops Revenue Estimates
09:53am, Thursday, 04'th Mar 2021
Arbutus (ABUS) delivered earnings and revenue surprises of -9.52% and 12.49%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Recap: Arbutus Biopharma Q4 Earnings
08:10am, Thursday, 04'th Mar 2021
Shares of Arbutus Biopharma (NASDAQ:ABUS) fell 6.0% in pre-market trading after the company reported Q4 results. Quarterly Results Earnings per share rose 50.00% year over year to ($0.23), which misse
Is a Surprise Coming for Arbutus Biopharma (ABUS) This Earnings Season?
09:52am, Wednesday, 03'rd Mar 2021
Arbutus Biopharma (ABUS) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Assembly Bio/Arbutus Bio Start Testing Vebicorvir/AB-729 Triplet Therapy In HBV Infection
11:52am, Friday, 26'th Feb 2021
Assembly Biosciences Inc (NASDAQ: ASMB) and Arbutus Biopharma Corp (NASDAQ: ABUS) initiated a Phase 2 trial evaluating the former's vebicorvir (VBR), combined with the latter's AB-729 and stand
Trial will evaluate Assembly's core inhibitor candidate, vebicorvir, with Arbutus' RNAi therapeutic candidate, AB-729, and standard-of-care NrtI therapy
Arbutus: A Promising Pure-Play On The $2.13 Billion Global Hepatitis B Market
02:50pm, Monday, 25'th Jan 2021
Arbutus Biopharma Corporation is an industry-leading early clinical-stage biopharmaceutical company focused on developing a cure for patients with chronic hepatitis B virus.
Arbutus Announces 2021 Corporate Objectives and Provides Financial Update
07:30am, Monday, 25'th Jan 2021
2021 objectives leverage positive momentum in Arbutus' Hepatitis B research and development programs
Arbutus to Participate in Virtual Fireside Chat at H.C. Wainwright BioConnect 2021 Conference
08:00am, Monday, 04'th Jan 2021
WARMINSTER, Pa., Jan. 04, 2021 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company primarily focused on developing a cure for people with chron
Implied Volatility Surging for Arbutus Biopharma (ABUS) Stock Options
09:47am, Tuesday, 15'th Dec 2020
Investors need to pay close attention to Arbutus Biopharma (ABUS) stock based on the movements in the options market lately.
Arbutus Announces Robust HBsAg Decline Data with AB-729 Dosed at 60 mg Every 8 Weeks in Chronic Hepatitis B Subjects
07:30am, Thursday, 10'th Dec 2020
Repeat dosing of 60 mg AB-729 every 8 weeks resulted in mean HBsAg declines of –1.37 log10 (N=6) comparable to AB-729 dosed every 4 weeks ( –1.44 log10, N=7, p
Arbutus Announces Additional Robust HBsAg Decline Data with AB-729 in Chronic Hepatitis B Subjects
07:00am, Monday, 16'th Nov 2020
Data released today expands on November 15, 2020 AASLD presentation
Across all single-dose cohorts, mean HBsAg concentrations continuously declined up to week 12 before reaching a plateau , suggesting dosing of AB-729 less frequently than every 4 weeks may be warrante
Arbutus to Present at Jefferies Virtual London Healthcare Conference
08:00am, Tuesday, 10'th Nov 2020
WARMINSTER, Penn., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company primarily focused on developing a cure for people with chr
Arbutus Biopharma Corporation (ABUS) CEO Bill Collier on Q3 2020 Results - Earnings Call Transcript
03:11pm, Thursday, 05'th Nov 2020
Arbutus Biopharma Corporation (ABUS) CEO Bill Collier on Q3 2020 Results - Earnings Call Transcript
